These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 15621736

  • 1. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C, Stavroyianni N, Saloum R, Tsompanakou A, Anagnostopoulos A.
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [Abstract] [Full Text] [Related]

  • 2. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 5. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
    Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C.
    Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 7. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 8. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
    Al-Ahmad M, Al-Rasheed M, Al-Muhani A.
    J Investig Allergol Clin Immunol; 2010 Mar; 20(3):259-62. PubMed ID: 20635793
    [Abstract] [Full Text] [Related]

  • 9. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.
    Cohen Y, Polliack A.
    Hematol J; 2002 Mar; 3(1):61-2. PubMed ID: 11960398
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 11. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [Abstract] [Full Text] [Related]

  • 12. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
    Tanai C, Iki S, Nakahara F, Iijima K, Usuki K, Kuwana M, Urabe A.
    Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
    [Abstract] [Full Text] [Related]

  • 13. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 14. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H, Gruhn B, Werner U, Schorner U, Häfer R, Zintl F, Barz D.
    Acta Haematol; 2004 Oct; 111(4):221-4. PubMed ID: 15153715
    [Abstract] [Full Text] [Related]

  • 15. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY, Zhang Z, Song LX, Gzhang X, Su JY, Li X, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
    [Abstract] [Full Text] [Related]

  • 16. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 17. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Pagano A, Stipa E, Amadori S.
    Blood; 2001 Aug 15; 98(4):952-7. PubMed ID: 11493438
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
    Riksen NP, Keuning JJ, Vreugdenhil G.
    Neth J Med; 2003 Jul 15; 61(7):262-5. PubMed ID: 14567524
    [Abstract] [Full Text] [Related]

  • 19. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
    Hegde UP, Wilson WH, White T, Cheson BD.
    Blood; 2002 Sep 15; 100(6):2260-2. PubMed ID: 12200396
    [Abstract] [Full Text] [Related]

  • 20. [Use of rituximab in resistant thrombocytopenic purpura].
    Zambrano-Velarde MA, de la O-Peña D, Chávez-Peña Q, Bedolla-Barajas M.
    Rev Med Inst Mex Seguro Soc; 2012 Sep 15; 50(2):203-8. PubMed ID: 22882991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.